ORDENTLICH PETER (Chief Scientific Officer) sold 1.41K shares of SYNDAX PHARMACEUTICALS INC on the open market
Open‑market sale worth $23.5K. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/3/2022ACC: 0001562180-22-001079
Officer· Chief Scientific Officer
Since Feb 2019
+80K
Net shares
Net buyer
$23.5K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
81.41K acquired · 1.41K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+1.41K
Price / share
$12.39
Trade value
$17.49K
% of position
New position
1/31/2022
0.00→1.41K
Common Stock
Direct
Shares
−1.41K
Price / share
$16.65
Trade value
$23.51K
% of position
New position
2/1/2022
1.41K→0.00
Total
Net shares
+0.00
Net value
-$6.02K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/31/2022 | J · J | +1.41K | $12.39 | $17.49K | New position | 0.00 | 1.41K |
| Common Stock Direct | 2/1/2022 | S · Sale | −1.41K | $16.65 | $23.51K | New position | 1.41K | 0.00 |
| Total | +0.00 | -$6.02K | ||||||
Derivative Transactions1
Stock Options (Right to buy)
Direct
Converts to
Common Stock
80K shares
Shares
+80K
Strike price
15.79
Held after
80K
Exercisable
—
2/2/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy) Direct | Common Stock80K shares | 2/2/2022 | A · Award | +80K | 15.79 | — | 80K |